The Clinical Data for Injections In the SUSTAIN and STEP clinical trials, injectable semaglutide showed remarkable results
8.4.4 Translation of preclinical evidence to clinical practice: critical methodological gaps A systematic evaluation of the evidence base presented in this review reveals significant translational barriers between preclinical mechanistic studies and clinical efficacy validation
For patients with significant obesity or related conditions, that risk-benefit calculation tends to come out clearly in favor of treatment
Many people report a noticeable reduction in hunger and fewer food cravings
In principle, similar persister-aware high-throughput screens could be adapted to investigate probiotic secretomes (i.e., cell-free supernatants and fractionated metabolomes) to systematically identify molecular motifs capable of killing or sensitizing fungal persisters, rather than solely inhibiting growth
Clinical evidence supports it: The SEMALEAN study (2025) found a 15% reduction in visceral fat and an average of 12 kg total weight loss over six months